Home › Drug Reactions › NCT06766071

IPGx PILOT Whole Genome Sequencing Extension Cohort

The Texas A&M Interprofessional Pharmacogenomics PILOT Whole Genome Sequencing (WGS) Cohort

Who can join

Ages 18 to 100 · All sexes

Inclusion Criteria:

* Individuals taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs.
* Ability to give and comprehend the consent process.
* Consent to donate urine samples, genetic data through buccal swabs and blood samples, and undergo a comprehensive history and physical examination.
* All genders
* Age 18-100

Exclusion Criteria:

* Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.
* Admitted to hospice.
* Patient has ever been diagnosed with Hepatitis B or C.
* Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \>10, ALT, or AST \>100U/L or an AST/ALT ratio \>2
* Patients taking imidazole antifungal medication.
* Declines to participate or interact with staff/share their medical status.
* A diagnosis of Alzheimer's disease or related dementias in a medical record indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.
* Pregnant patients will be excluded.
* Individuals who are unable or unwilling to provide consent will be excluded.
* Unable to verbally communicate and comprehend English language.

About the study

The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice including Whole Genome Sequencing (WGS).

Sponsor: Texas A&M University · Participants: 50 · Started: 2025-01

Contact the study team

• Kenneth S Ramos,, MD · Phone: 7136777740
• Rick Silva, PhD · Phone: (713) 677-7422

Official record on ClinicalTrials.gov — NCT06766071

Locations in the U.S.

Conditions

• Drug Reactions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.